Predictors of Long-Term Immunological Outcome in Rebounding Patients on Protease Inhibitor-Based HAART After Initial Successful Virologic Suppression: Implications for Timing to Switch

REFERENCES

• Palella FJJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860.
   PubMed Web of Science ®Google Scholar
• Palella FJ, Cmiel JS, Moorman AC, Holmberg SD, and the HIV Outpatient Study Investigators. Durability and predic-tors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS. 2002;16:1617–1626.
   PubMed Web of Science ®Google Scholar
• Yeni PG, Hammer SM, Carpenter CCJ, et al. Antiretroviral treatment for adult HIV infection in 2002. JAMA. 2002;288:222–235.
   PubMed Web of Science ®Google Scholar
• Egger M, May M, Chene G, et al. Prognosis of HIV-1 infected patients starting HAART: a collaborative analysis of prospective studies. Lancet. 2002;360:119–126.
   PubMed Web of Science ®Google Scholar
• d'Arminio Monforte A, Testori V, Adorni F, et al. CD4+ cell counts at the third month of HAART may predict clinical failure. AIDS. 1999;13:1669–1676.
   PubMed Web of Science ®Google Scholar
• Piketty C, Weiss L, Thomas F, et al. Long-term clinical outcome of human immunodeficiency virus-infected pa-tients with discordant response to a protease inhibitor-containing regimen. J Infect Dis. 2001183: 1328–1335.
   Google Scholar
• Wood E, Benita Y, Hogg RS, et al. Full suppression of viral load is needed to achieve an optimal CD4+ cell count response among patients on triple drug antiretroviral therapy. AIDS. 2000;14:1955–1960.
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Service (DHHS) and the Henry Kaiser Family Foundation. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adoles-cents. February 4,2002; http://www.hivatis.org
   Google Scholar
• Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4+ cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS. 1999;13(6):F35–43.
   PubMed Web of Science ®Google Scholar
• Ledergerber B, Egger M, Opravil M, et al. Clinical progres-sion and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lan-cet. 1999;353:863–868.
   PubMed Web of Science ®Google Scholar
• Phillips AN, Miller V, Sabin C, et al. Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals. AIDS. 200115: 2379–2384.
   Google Scholar
• Grabar S, Le Moing V, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med. 2000;133:401–410.
   PubMed Web of Science ®Google Scholar
• Piketty C, Castiel P, Belec L, et al. Discrepant responses to triple combination therapy in advanced HIV disease. AIDS. 1998;12:745–750.
   PubMed Web of Science ®Google Scholar
• Phenix BN, Angel JB, Mandy F, et al. Decreased HIV-associated T-cell apoptosis by HIV protease inhibitors. AIDS Res Hum Retro viruses. 2000;16:559–567.
   PubMed Web of Science ®Google Scholar
• Croteau G, Doyon L, Thibeault D, et al. Impaired fitness of human immunodeficiency virus type 1 variants with high level resistance to protease inhibitors. J Virol. 1997;71:1089–1096.
   PubMed Web of Science ®Google Scholar
• Stoddart CA, Liegler TJ, Mammano F, et al. Impaired repli-cation of protease inhibitor-resistant HIV-1 in thymus. Na-ture Med. 2001;7: 712–718.
   PubMed Web of Science ®Google Scholar
• Paraninfo G, Pan A, Castelli F, et al. The MASTER cohort data base: a software to manage HIV patients. In: Program and abstracts from the XIV International Conference on AIDS; July 7–12, 2002; Barcelona, Spain. Abstract MoPeB3213.
   Google Scholar
• Erice A, Brambilla D, Bremer J, et al. Performance charac-teristics of the Quantiplex HIV-RNA 3.0 assay for detection and quantitation of human immunodeficiency virus type 1 in plasma. J Clin Microbiol. 2000;38:2837–2845.
   PubMed Web of Science ®Google Scholar
• Senn S, Stevens L, Chaturvedi N. Repeated measures in clinical trials: simple strategies for analysis using summary measures. Statistics Med. 2000;19:861–877.
   PubMed Web of Science ®Google Scholar
• Carosi G, Castelli F, Suter F, et al. Anti-viral potency of HAART regimens and clinical success are not strictly coupled in real life conditions. Evidence from the MASTER-1 Study. HIV Clin Trials. 2001;2(5):399–407.
   PubMedGoogle Scholar
• Wood E, Hogg RS, Yip B, et al. "Discordant" increase in CD4+ cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy. J Acquir Immune Defic Syndr. 200230: 159–166.
   Google Scholar
• Deeks SG, Barbour JD, Martin JN, Swanson MS, Grant RN. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis. 2000;181:946–953.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4+ T-cell gain in patients who continue combination therapy despite detectable plasma viremia. AIDS. 2002;16:201–207.
   PubMed Web of Science ®Google Scholar
• Thiébaut R, Morlat P, Jacqmin-Gadda DN, et al. Clinical progression of HIV infection according to the viral response during the first year of antiretroviral treatment AIDS. 2000;14:971–978.
   Google Scholar
• Le Moing V, Thiebaut R, Chene G, et al. Predictors of long-term increase in CD4+ cells counts in human immunodefi-ciency virus-infected patients receiving a protease inhibi-tor-containing antiretroviral regimen. J Infect Dis. 2002;185:471–480.
   PubMed Web of Science ®Google Scholar
• Belec L, Piketty C, Si-Mohammed A, et al. High level of drug-resistant human immunodeficiency virus variants in patients exhibiting increasing CD4+ T cell counts despite virological failure of protease inhibitor-containing antiretroviral combination therapy. J Infect Dis. 2000;181:1808–1812.
   PubMed Web of Science ®Google Scholar
• Bennett KK, DeGruttola VG, Marschner IC, et al. Baseline predictors of CD4+ T-cell recovery with combination antiretroviral therapy. J AIDS. 2002;31:20–26.
   PubMed Web of Science ®Google Scholar
• Carosi G, Suter F, Maggiolo F, et al. HAART may be safely started when CD4+ count is 201–350 cells/ml. Evidence from the MASTER-1 study. In: Program and abstracts from the 1st IAS Conference on HIV Pathogenesis and Treat-ment; July 8–11, 2001; Buenos Aires. Abstract 231.
   Google Scholar
• Cozzi Lepri A, Phillips A, d'Arminio Monforte A, et al. When to start active antiretroviral therapy in chronically HIV-in-fected patients: evidence from the ICONA study. AIDS. 200115: 983–990.
   Google Scholar
• Kaufmann GR, Bloch M, Finlayson R, et al The extent of HIV-1 related immunodeficiency and age predict the long-term CD4+ T-lymphocyte response to potent antiretroviral therapy. AIDS. 2002;16:359–367.
   PubMed Web of Science ®Google Scholar
• Dronda F, Moreno S, Moreno A, et al. Long-term outcomes among antiretroviral-naive human immunodeficiency virus-infected patients with small increases in CD4+ cell counts after successful virologic suppression. Clin Infect Dis. 2002;35:1005–1009.
   PubMed Web of Science ®Google Scholar
• Landay AL, Bettendorf D, Chan E, et al. Evidence of im-mune reconstitution in antiretroviral drug-experienced pa-tients with advanced HIV disease. AIDS Res Hum Retroviruses. 2002;18:95–102.
   PubMed Web of Science ®Google Scholar
• Raboud JM, Rae S, Woods R, et al. Consecutive rebounds in plasma viral load are associated with virological failure at 52 weeks among HIV-infected patients. AIDS. 2002;16:1627–1632.
   PubMed Web of Science ®Google Scholar
• Bahrani A, Ramaswany R, Oldfield EC III. Effects of viro-logic rebound on CD4+ cell count. Clin Infect Dis. 200132: 1231–1232.
   Google Scholar
• Tomasoni L, Patroni A, Uccelli MC, et al. Long-term immu-nological benefit in patients with discordant response to therapy depends on both level of viremia and duration of rebound. J Infect Dis. 2002;186:445–446.
   PubMed Web of Science ®Google Scholar
• Aleman S, Soderbarg K, Visco-Comadini U, et al. Drug-resistance at low viremia in HIV-1 infected patients with antiretroviral combination therapy. AIDS. 200216: 1039–1044.
   Google Scholar
• Greub G, Ledergerber B, Battegay M, et al. Clinical pro-gression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus co-infection: the Swiss Cohort Study. Lancet. 2000;356:1800–1805.
   PubMed Web of Science ®Google Scholar
• Taffé P, Rickenbach M, Hirschel B, et al. Impact of occa-sional short interruptions of HAART on the progression of HIV infection: results from a cohort study. AIDS. 2002;16:747–755.
   PubMed Web of Science ®Google Scholar